The global Neurofibromatosis and Schwannomatosis Therapeutics Market is set to experience robust expansion, growing from USD 1.1 billion in 2026 to USD 2.3 billion by 2036 at a Compound Annual Growth Rate (CAGR) of 7.7%.
The market entered 2026 up from USD 1.0 billion in 2025, catalyzed by the approval of mirdametinib (GOMEKLI)—the second...